The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. Foghorn has a collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company operates in the precision therapeutics space targeting multiple cancer indications with its chromatin-targeting approach.
Cyborg Score Rationale
The company has demonstrated significant revenue growth over the past three years with a 127.5% growth rate. However, the Altman Z-Score of -3.95 places the company in the distress zone, suggesting potential bankruptcy risk within two years. FHTX has underperformed the market significantly with a -47.6% price return over the last year.
Top Insights
Ryan Maynard appointed as new CFO effective February 23, 2026, bringing biopharmaceutical finance expertise
Pipeline targets multiple cancer types including prostate cancer, bladder cancer, NSCLC, lymphomas, leukemias, melanoma, and solid tumors
Current ratio of 2.16 indicates adequate liquidity but distressed Altman Z-Score signals financial strain
Stock exhibits high volatility with beta of 4.98
Named Competitors
Proteolysis-targeting chimera (PROTAC) — Protein degradation for cancer
Targeted protein degradation — Chromatin and epigenetic targets